← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOANALEPTICS › PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS › Centrally acting sympathomimetics
lisdexamfetamine
N06BA12
Forms & Strengths
- Capsules: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg
- Chewable Tablets: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg
Adult Dosing
- ADHD: Initial 30 mg orally once daily in the morning; may increase in increments of 10 mg to 20 mg at weekly intervals; maximum 70 mg/day
- Binge Eating Disorder (BED): Initial 30 mg orally once daily in the morning; titrate by 20 mg at weekly intervals to target 50 to 70 mg/day; maximum 70 mg/day
Pediatric Dosing
- ADHD (Children 6 years and older): Initial 30 mg orally once daily in the morning; may increase by 10 mg to 20 mg at weekly intervals; maximum 70 mg/day
- ADHD (Children under 6 years): Safety and efficacy not established
Indications
- Attention Deficit Hyperactivity Disorder (ADHD)
- Moderate to severe Binge Eating Disorder (BED) in adults
Mechanism of Action
- Prodrug of d-amphetamine; upon oral ingestion, lisdexamfetamine is converted to d-amphetamine and l-lysine
- Blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space
Contraindications
- Known hypersensitivity to amphetamine products or other ingredients in lisdexamfetamine
- Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of stopping MAOIs due to risk of hypertensive crisis
Adverse Reactions
- Decreased appetite
- Insomnia
- Dry mouth
- Increased heart rate and palpitations
- Weight loss
- Anxiety and irritability
- Nausea and upper abdominal pain
Drug Interactions
- Monoamine oxidase inhibitors (MAOIs): Risk of severe hypertensive crisis; contraindicated
- Acidifying agents (e.g., ascorbic acid): May decrease blood levels and efficacy of amphetamines
- Alkalinizing agents (e.g., sodium bicarbonate): May increase blood levels and toxicity of amphetamines
- Serotonergic drugs (e.g., SSRIs, SNRIs, triptans): Increased risk of serotonin syndrome when co-administered with amphetamines
- Antihypertensive agents: Amphetamines may diminish the hypotensive effects of these drugs
Curated Content: Needs Vetting Before Put to Clinical Use